Rheumatoid Arthritis

The FDA is requesting a new clinical study before evaluating a new drug application for baricitinib, an oral medication for moderate-to-severe rheumatoid arthritis.

Officials with the FDA are requesting a new clinical study before Eli Lilly and Incyte Corporation can resubmit for a new drug application (NDA) for baricitinib, a once-daily oral medication for moderate-to-severe rheumatoid arthritis treatment.

New treatments for inflammatory conditions, cancer, and HIV are on the horizon. 

Renflexis is indicated for the same inflammatory conditions as reference drug infliximab.

Renflexis is a biosimilar of Remicade, which treats inflammatory conditions, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.

The anticipated action date for drug that treats moderate-to-severe active ulcerative colitis is set for March 2018.

Findings confirm no or negligible placental transfer of anti-TNF drug in women with rheumatoid arthritis.

The trial is the first to compare Xeljanz alone or in combination with MTX versus adalimumab plus MTX.

Boehringer Ingelheim seeks to launch its biosimilar to Humira.

Research may lead to the development of safer therapies for pregnant women with rheumatoid arthritis.

Changing from a biologic to a biosimilar can create insecurity among patients with RA.

Clinical trial shows efficacy of Janus kinase inhibitor and methotrexate.

Trial evaluates tofacitinib versus adalimumab in the treatment of rheumatoid arthritis.

Sandoz has the highest number of biosimilars approved in Europe.

Rheumatoid arthritis should be included to list of medical conditions linked to obesity.

Findings suggest an association between lower disease activity and a higher intake of fish.

CT-P10 is indicated to treat rheumatoid arthritis, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangi.

Accumulation of gene mutations occurs in some patients with rheumatoid arthritis, study finds.

Sarilumab (Kevzara) is a humanized monoclonal antibody that treats moderate-to-severe active RA.

The guidelines aim to reduce the risk of infection in patients administered anti-rheumatic medication.

The tool can help reduce the cost of treatment for rheumatoid arthritis.

CT-P10 is indicated to treat a form of non-Hodgkin lymphoma and rheumatoid arthritis.

New analysis examines opioid use among patients with rheumatoid arthritis.

Rheumatoid arthritis carries risks for several comorbidities that can affect organ systems, such as the heart and lungs.

Novel vaccine modulates T cell responses in RA.

Exposure to secondhand smoke in children can lead to RA later in life.

Top articles of the week on Specialty Pharmacy Times.

Additional support programs found to benefit the physical and emotional needs of patients with RA.

Eli Lilly will present 27 abstracts on the safety and long-term efficacy for rheumatoid arthritis and psoriasis drugs.

The drug offers a new therapeutic option to help manage RA.